FDA Approves New Medtronic Left-Heart Lead

The Food and Drug Administration has approved the availability of Medtronic’s Attain Ability left-heart lead for use with cardiac resynchronization therapy devices for heart failure patients, according to a Medtronic news release.

Advertisement

Attain Ability has the thinnest lead body of any left-heart lead currently available, which can permit physicians to deliver therapy directly to hard-to-reach areas of the heart.

Attain Ability incorporates insulation material developed by NASA Langley Research Center in Hampton, Va., that was previously evaluated for space applications, high-performance engines and harsh environments. This application marks the first time a NASA-developed material has been used in this kind of implantable medical device.

Read the Medtronic release on the Attain Ability left-heart lead.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.